MLM Share Price

Open 0.44 Change Price %
High 0.46 1 Day 0.01 2.27
Low 0.43 1 Week 0.09 25.00
Close 0.45 1 Month 0.09 25.00
Volume 10587635 1 Year 0.08 21.62
52 Week High 0.64
52 Week Low 0.22
MLM Important Levels
Resistance 2 0.48
Resistance 1 0.47
Pivot 0.45
Support 1 0.43
Support 2 0.42
BIT Italy Most Active Stocks
UCG 2.50 -2.34%
PMI 0.35 -5.41%
PMI 0.35 -5.41%
ISP 2.36 -1.67%
SPM 0.44 -2.22%
SPM 0.44 -2.22%
TIT 0.76 0.00%
ENEL 3.97 0.25%
BP 2.25 -3.85%
BP 2.25 -3.85%
More..
BIT Italy Top Gainers Stocks
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
ACO 3.92 15.29%
ACO 3.92 15.29%
ARN 2.85 8.78%
ARN 2.85 8.78%
MIC 4.31 7.75%
MIC 4.31 7.75%
More..
BIT Italy Top Losers Stocks
ECA 0.04 -20.00%
ECA 0.04 -20.00%
ECA 0.04 -20.00%
POPR 0.23 -11.54%
BMPS 19.50 -10.55%
PRL 0.17 -5.56%
PMI 0.35 -5.41%
PMI 0.35 -5.41%
CVAL 0.37 -5.13%
BPSO 3.18 -4.79%
More..

Molmed (BIT: MLM)

MLM Technical Analysis 3
As on 9th Dec 2016 MLM Share Price closed @ 0.45 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.37 & Buy for SHORT-TERM with Stoploss of 0.40 we also expect STOCK to react on Following IMPORTANT LEVELS.
MLM Target for December
1st Target up-side 0.37
2nd Target up-side 0.4
3rd Target up-side 0.44
1st Target down-side 0.27
2nd Target down-side 0.24
3rd Target down-side 0.2
MLM Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.molmed.com
MLM Address
MLM
Via Olgettina, 58
Milan, MI 20132
Italy
Phone: 39 02 212771
Fax: 39 02 21 27 73 25
Interactive Technical Analysis Chart Molmed ( MLM BIT Italy )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Molmed
MLM Business Profile
MolMed S.p.A., a medical biotechnology company, focuses on the research, development, and clinical validation of therapies to treat cancer. Its products include TK, a cell therapy product, which is in Phase III clinical trials enabling safe transplant of haematopoietic stem cells from partially compatible haplo-identical donors for the treatment of haematological malignancies. The company’s products also comprise NGR-hTNF, a recombinant biological drug that is in Phase II clinical trials for various types of solid tumours, such as colorectal, hepatocellular carcinoma and mesothelioma, small-cell lung cancer, non-small cell lung cancer, ovarian cancer, and soft-tissue sarcoma, as well as is in Phase III clinical trials in mesothelioma patients. It has an agreement with Telethon Foundation for the co-development and clinical-grade manufacture of gene therapies for rare genetic diseases; San Raffaele Foundation for the clinical-grade manufacturing of a cell therapy for Duchenne muscular dystrophy; and GlaxoSmithKline for the development and production for clinical use of a viral vector for ADA, as well as a strategic partnership with Takara Bio, Inc. for TK cell therapy. The company was founded in 1996 and is based in Milan, Italy.